Immunohistochemistry in assessment of molecular pathogenesis of cervical carcinogenesis

Concerning the prediction of HPV-associated cervical disease, several importance issues are related both to the management of women with diagnosed CIN and those with cervical cancer. Oncogenic HPVs are capable of contributing to the development of malignant phenotype by several different mechanisms, most of which seem to be closely interrelated. Because of the fact that these molecular interactions are mediated by proteins, the logical strategy to dissect the complex molecular pathways is to study the functions of these proteins, utilising the capabilities of immunohistochemistry (IHC). IHC offers practically unlimited possibilities to study any target molecules, against which a monoclonal or polyclonal antibody can be raised. This review describes the IHC-based strategies used by this author to assess the molecular pathogenesis of cervical cancer and its precursors in a number of large-scale prospective cohort studies conducted during the past 25 years. In the ongoing HPV-PathogenISS study, 13 different markers are being tested to evaluate their predictive value in distinct viral events, e.g. persistence or clearance of high-risk HPV in women treated for CIN. Apart from getting new insights into the molecular pathogenesis of HPV-associated cervical carcinogenesis, we anticipate the disclosure of individual markers, a set of markers, or an expression profile of any such marker sets that would be of clinical value as predictors of disease outcome in cervical carcinogenesis.

Human papillomavirus; Immunohistochemistry; Cervical cancer; CIN; Biomarker; Prognosis

[1] IARC Monographs on the evaluation of carcinogenic risks to humans. Papillomaviruses. Lyon. IARC, 1995, 64, 1.

[2] zur Hausen H.: "Cervical carcinoma and human papillomavirus: on the road to preventing a major human cancer". J. Natl. Cancer Inst., 2001, 93, 252.

[3] zur Hausen H.: "Papillomaviruses and cancer: from basic studies to clinical application". Nature Rev. Cancer, 2002, 2, 342.

[4] Syrjlinen K., Syrjlinen S.: "Papillomavirus Infections in Human Pathology". Chichester, J. Wiley & Sons, 2000, 1.

[5] Aubin F., Pretet J.L., Mougin C. (eds.).: "Papillomavirus humains. Biologie et pathologie tumorale". Paris, Editions TEC & DOC, 2003, 1.

[6] Bosch F.X., de Sanjose S., Chapter 1: "Human papillomavirus and cervical cancer-burden and assessment of causality". J. Natl. Cancer Inst. Monogr., 2003, 31, 3.

[7] Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V. et al.: "Epidemiologic classification of human papillomavirus types associated with cervical cancer". N. Engl. J. Med., 2003, 348, 518.

[8] von Knebel Doeberitz M.: "New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillo mavirus infections". Eur. J. Cancer, 2002, 38, 2229.

[9] Ostor A.G.: "Natural history of cervical intraepithelial neoplasia - a critical review". Int. J. Gynecol. Pathol., 1993, 12, 186.

[10] Syrjannen K.J.: "Natural history of cervical HPV infections and CIN". Chapter 6. In: Syrjanen'K. and Syrjlinen S.: "Papillomavirus infections in human pathology". J. Wiley & Sons, New York, 2000, 142.

[11] Bosch F.X., Munoz N.: "The viral etiology of cervical cancer". Virus Res., 2002, 89, 183.

[12] Syrjlinen K.J.: "Natural history of HPV infections: Recent developments". In: Monsonego J. (ed.) 5th International Multidisciplinary Congress EUROGIN 2003. Milano, Monduzi Editore, 2003, 1.

[13] Ferenczy A., Franco E.: "Persistent human papillomavirus infection and cervical neoplasia". Lancet Oncol., 2003, 3, 11.

[14] Cuzick J., Sasieni P.: "Natural history of cervical human papillomavirus". Lancet, 2001, 358, 1550.

[15] Duggan M.A.: "A review of the natural history of cervical intraepithelial neoplasia". Gan To Kagaku Ryoho., 2002, 29 (suppl. 1), 176.

[16] Paraskevaidis E., Kaponis A., Malamou-Mitsi V., Davidson E.J., Hirsch P.M., Koliopoulos G.: "The natural history of HPV infection of the uterine cervix. Long-term observational and histological data". Anticancer Res., 2002, 22, 1177.

[17] Franco E.L., Villa L.L., Sobrinho J.P., Prado J.M., Rousseau M.C., Desy M.: "Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer". J. Infect. Dis., 1999, 180, 1415.

[18] Giuliano A.R., Harris R., Sedjo R.L., Baldwin S., Roe D., Papenfuss M.R. et al.: "Incidence, prevalence, and clearance of typespecific human papillomavirus infections: The Young Women's Health Study". J. Infect. Dis., 2002, 186, 462.

[19] Sellors J.W., Karwalajtys T.L., Kaczorowski J., Mahony J.B., Lytwyn A., Chong S. et al.: "Incidence, clearance and predictors of human papillomavirus infection in women". Can. Med. Ass. J., 2003, 168, 421.

[20] Moscicki A.B., Shiboski S., Broering J., Powell K., Clayton L., Jay N. et al.: "The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women". J. Pediatr., 1998, 132, 277.

[21] Liaw K.L., Glass A.G., Manos M.M., Greer C.E., Scott D.R., Sherman M. et al.: "Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions". J. Natl. Cancer Inst., 1999, 91, 954.

[22] Winer R.L., Lee S.K., Hughes J.P., Adam D.E., Kiviat N.B., Koutsky L.A.: "Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students". Am. J. Epidemiol., 2003, 157, 218.

[23] Woodman C.B., Collins S., Winter H., Bailey A., Ellis J., Prior P. et al.: "Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study". Lancet, 2001, 357, 1831.

[24] Rozendaal L., Westerga J., van der Linden J.C., Walboomers J.M., Voorhorst F.J., Risse E.K. et al.: "PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes". J. Clin. Pathol., 2000, 53, 606.

[25] Moscicki A.B., Hills N., Shiboski S., Powell K., Jay N., Hanson E. et al.: "Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females". JAMA, 2001, 20, 285, 2995.

[26] Nobbenhuis M.A., Helmerhorst T.J., van den Brule A.J., Rozendaal L., Voorhorst F.J., Bezemer P.O. et al.: "Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear". Lancet, 2001, 358, 1782.

[27] Schiffman M., Wheeler C.M., Castle P.E.: "Human papillomavirus DNA remains detectable longer than related cervical cytologic abnormalities". J. Infect. Dis., 2002, 186, 1169.

[28] Nobbenhuis M.A., Helmerhorst T.J., van den Brule A.J., Rozendaal L., Bezemer P.O., Yoorhorst F.J. et al.: "High-risk human papillomavirus clearance in pregnant women: trends for lower clearance during pregnancy with a catch-up postpartum". Br. J Cancer, 2002, 87, 75.

[29] Giuliano A.R., Sedjo R.L., Roe D.J., Harri R., Baldwi S., Papenfuss M.R.: "Clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States)". Cancer Causes Control, 2002, 13, 839.

[30] Zielinski D.G., Snijders P.J., Rozendaal L., Voorhorst F.J., Runsink A.P., de Schipper F.A., Meijer C.J.: "High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance".]. Pathol., 2001,1 95, 300.

[31] Costa S., Simone P.O., Yenturoli S., Cricca M., Zerbini M.L., Musiani M. et al.: "Factors predicting Human papillomavirus (HPY ) clearance in cervical intraepithelial neoplasia (CIN) lesions treated by conization". Gynecol. Oncol., 2003, 90, 358

[32] Nobbenhuis M.A.E., Meijer C.J.L.M., van den Brule A.J.C., Rozendaal L., Voorhorst F.J., Verheijen R.H.M., Helmerhorst T.J.M.:"Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia". Brit. J. Cancer, 2001, 84, 796.

[33] Paraskevadis E., Koliopuolos G., Alamanos Y., Malamoumitsi V., Lolis E.D., Kitchener H.C.: "Human papillomavirus testing in the prediction of the outcome of treatment for cervical intraepithelial neoplasia". Ob stet. Gynecol., 2001, 98, 833.

[34] Syrjanen K.J., Er_en M., Costa S.: "Histological and quantitative pathological prognostic factors in cervical cancer". CME J Gynec. Oneal., 2001, 6, 279.

[35] Syrjanen K.J., Erzen M.: "The prognostic significance of Human papillomavirus (HPV) infections and cancer screening". CME J. Gynec. Oncol., 2001, 6, 325.

[36] Syrjanen K.J.: "Summary statements on prognostic factors in carcinoma of the uterine cervix". CME]. Gynec. Oncol., 2003, 8, 298.

[37] Branca M., Garbuglia A.-R., Benedetto A., Leoncini L., Migliore G., Cappiello T. et al.: "Factors predicting the persistence of genital Human papillomavirus (HPV) infections and PAP smear abnormality in HIV-positive and HIV-negative women during prospective follow-up". Int. J. STD & AIDS, 2003, 14,417.

[38] Vassallo J., Derchain S.F., Pinto G.A., Martinez E.Z., Syrjanen K.J., Andrade L.A.: "High risk HPV and p53 protein expression in cervical intraepithelial neoplasia". Int. J. Obstet. Gynecol., 2000, 71, 45.

[39] Kataja V.,S yrjanen K.,S yrjanen S.,M antyjarvi R.,Y liskoski M.,S aarikoski S.,S alonen J.T.: "Prognostic factors in cervical human papillomavirus (HPV) infections". Sex Transm. Dis., 1992, 19, 154.

[40] Ferreira Santos A.L., Derchain S.F.M., Martins M.R., Sarian L.O.Z., Martinez E.Z., Syrjanen K.J.: "Human papillomavirus (HPV) viral load in predicting high-grade CIN in women with PAP smears showing only atypical squamous cells (ASC) or low grade squamous intraepithelial lesion (LSIL)". Sao Paulo Med.]., 2003, 121, 238.

[41] Syrjanen K.: "Pathogenesis of HPV infections". In: Syrjanen K. and Syrjanen S. (eds.): "Papillomavirus Infections in Human Pathology". New York, J. Wiley & Sons, 2000, 3, 53.

[42] Syrjanen S., Syrjanen K.: "Molecular biology of papillomaviruses". In: Syrjanen K. and Syrjanen S. (eds.): "Papillomavirus Infections in Human Pathology". New York, J. Wiley & Sons, 2000, 2, 11.

[43] Cann A.J.: "Principles of Molecular Virology" (2"'ed.). San Diego, Academic Press, 1997, 1.

[44] Tervahauta A., Syrjanen S., Syrjanen K.: "Epidermal growth factor receptor (EGF-R), c-erbB-2 proto-oncogene and estrogen receptor (ER) expression in Human papillomavirus (HPV) lesions of the uterine cervix". Int. J. Gynecol. Pathol., 1994, 13, 234.

[45] Hietala K., Kosma V-M., Syrjanen K., Syrjanen S., Kellokoski J.: "Correlation of MIB-1 antigen expression with transcription factors Skn-1, Oct-1, AP-2 and HPV type in cervical intraepithelial neoplasia". J. Pathol., 1997, 183, 305.

[46] Tosi P., Pallini V., Cintorino M., Bugnoli M., Covacci A., Petracca R. et al.: "Use of antibodies against a synthetic peptide of the E6 protein of human papillomavirus (HPV) type 16 for the diagnosis of genital HPV lesions". Cytopathol., 1993, 4, 3.

[47] Syrjanen S.M., Syrjanen K.J.: "New concepts on the role of human papillomavirus in cell cycle regulation". Ann. Med., 1999, 31, 175.

[48] Brenna S.M.F., Syrjanen K.J.: "Regulation of cell cycle is of key importance in human papillomavirus (HPV)-associated cervical carcinogenesis". Sao Paulo Med. J., 2003, 121, 128.

[49] Crusius K., Auvinen E., Steuer B., Gaissert H., Alonso A.: "The human papillomavirus type 16 E5-protein modulates liganddependent activation of the EGF receptor family in the human epithelial cell line HaCaT". Exp. Cell. Res., 1998, 241, 76.

[50] Crusms k, Rodnguez I,Alonso A “T he human pap仆lomavlrus type 16 E5 protem modulates ERKIJ2 and p38 MAP kinnase activation by an EGFR-independent process in stressed human keratinocytes". Virus Genes., 2000, 20, 65.

[51] Syrjanen K.J., Pyrhi:inen S.: "Demonstration of human papilloma virus (HPV) antigen in the condylomatous lesions of the utenne cervix by immunoperoxidase technique". Gynecol. Obstet. Invest., 1982, 14, 90.

[52] Syrjanen K.J.: "Human papillomavirus (HPV) lesions in association with cervical dysplasias and neoplasias". Obstet. Gynecol., 1983, 62, 617.

[53] Syrjanen K.J.: "Current concepts on Human papillomavirus (HPV) infections in the genital tract and their relationship to intraepithelial neoplasia and squamous cell carcinoma". Obstet. Gynecol. Surv., 1984, 39, 252.

[54] Tervahauta A., Syrjanen S.M., Vayrynen M., Saastamoinen J., Syrjanen K.: "Expression of p53 protein related to the presence of Human papillomavirus (HPV) DNA in genital carcinomas and precancer lesions". Anticancer Res., 1993, 13, 1107.

[55] Tervahauta A., Syrj却en S.M., Mantyj如R.,Syrjanen K.J.: "Detection of p53 protein and Ki-67 proliferation antigen in Human papillomavirus (HPV)-positive and HPV-negative cervical lesions by immunohistochemical double-staining". Cytopathol., 1994, 5, 282.

[56] Tervahauta A., Syrjanen S.,Y liskoski M.,G old L.I., Syrjanen K.: "Expression of transforming growth factorβ-1 and β-2 in human papillomavirus (HPV)-associated lesions of the uterine cervix". Gynecol. Oncol., 1994, 54, 349.

[57] Kurvinen K., Syrjanen K., Syrjanen S.: "p53 and bcl-2 proteins as prognostic markers in human papillomavirus-associated cervical lesions". J. Clin. Oncol., 1996, 14, 2120.

[58] Syrjanen S., Shabalova I.P., Petrovichev N., Kozachenko V.P., Zakharova T., Pajanidi A. et al.: "Human papillomavirus testing and conventional PAP smear cytology as optional screening tools of women at different risk for cervical cancer in countries of former Soviet Union". J. Lower Genital Tract Dis. 2002, 6, 97.

[59] Syrjanen S., Shabalova LP., Petrovichev N., Kozachenko V.P., Zakharova T., Pajanidi A. et al.: "Sexual habits and Human papillomavirus (HPV) infections among women in three new independent states of the fomer Soviet Union". Sex Transm Dis., 2003, 30, 680.

[60] Syrjanen S., Shabalova I.P., Petrovichev N., Kozachenko V.P., Zakharova T., Pajanidi A. et al.: "Acquisition of incident high-risk human papillomavirus (HPV) infections and PAP smear abnormalities in a cohort of women subjected to HPV screening inthe new independent states (NIS) of the former Soviet Union". J. Clin. Microbial., 2004, 42, 505.

[61] Syrjanen K., Naud P., Derchain S.M., Roteli-Martins C., Longatto-Filho A., Tatti S. et al.: "Comparing PAP smear cytology, aided visual inspection (VIA), screening colposcopy, cervicography and HPV testing by HCII (normal and self-sampling) as optional screening tools in Latin America. Experience from the LAMS study". In: Monsonego J. (ed.). 5th International Multidisciplinary Congress EUROGIN 2003. Monduzi Editore, Milano, 2003, 65.

[62] Syrjanen K., Naud P., Derchain S.M., Roteli-Martins C., Longatto-Filho A., Tatti S. et al.: "Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America". Study Design and Baseline Data of the LAMS Study. 21" International Papillomavirus Conference, Mexico City, February, 20, 2004.

[63] Branca M., Costa S., Mariani L., Piccione E., Sesti F., Agarossi A. et al.: "Assessment of risk factors and Human papillomavirus (HPV) related pathogenetic mechanisms of CIN in HIV-positive and HIV-negative women. Study design and baseline data of the HPV-PathogenISS study". Eur. J. Gynecol. Oncol., 2004. In press.

[64] Syrjanen K, Kataja V., Yliskoski M., Chang F., Syrjanen S., Saarikoski S.: "Natural history of cervical Human papillomavirus lesions does not substantiate the biologic relevance of the Bethesda System". Obstet. Gynecol., 1992, 79, 675.

[65] Mitchell M.F., Hittelman W.N., Hong W.K., Lotan R., Schottenfeld D.: "The natural history of cervical intraepithelial neoplasia: an argument for intermediate endpoint biomarkers". Cancer Epidemiol. Biomarkers Prev., 1994, 3, 619.

[66] Franco E.L., Duarte-Franco E., Ferenczy A.: "Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection". Can. Med. Ass. J., 2001, 164, 1017.

[67] Costa S., Terzano P., Santini D., Panetta A., Martoni A., Bovicelli A. et al.: "CD44 isoform 6 (CD44v6) is a prognostic indicators of the response to neoadjuvant chemotherapy in cervical carcinoma". Gynecol. Oncol., 2001, 80, 67.

[68] Costa S., Terzano P., Santini D., Ceccarelli C., Martoni A., Angelelli B. et al.: "Neoadjuvant chemotherapy in cervical carcinoma: regulators of cell cycle, apoptosis and proliferation as determinants of response to therapy and disease outcome". Am. J. Clin. Pathol., 2001, 116, 729.

[69] Davidson B., Goldberg I., Gotlieb W.H., Ben Baruch G., Kopolovic J.: "CD44 expression in uterine cervical intraepithelial neoplasia and squamous cell carcinoma: an immunohistochemical study". Eur. J. Gynaecol. Oncol., 1998, 19, 46.

[70] Jeffers M.D., Paxton J., Bolger B., Richmond J.A., Kennedy J.H., McNicol A.M.: "E-cadherin and integrin cell adhesion molecule expression in invasive and in situ carcinoma of the cervix". Gynecol. Oncol., 1997, 64, 481.

[71] Asha Nair S., Karunagaran D., Nair M.B., Sudhakaran P.R.: "Changes in matrix metalloproteinases and their endogenous inhibitors during tumor progression in the uterine cervix". J. Cancer Res. Clin. Oncol., 2003, 129, 123.

[72] Moser P.L., Kieback D.G., Hefler L., Tempfer C., Neunteufel W., Gitsch G.: "Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage IB cervical cancer". Anticancer Res., 1999, 19, 4391.

[73] Hashimoto I., Kodama J., Seki N., Hongo A., Yoshinouchi M., Okuda H., Kudo T.: "Vascular endothelial growth factor-C expression and its relationship to pelvic lymph node status in invasive cervical cancer". Br. J. Cancer, 2001, 85, 93.

[74] Lopez-Ocejo 0., Viloria-Petit A., Bequet-Romero M., Mukhopadhyay D., Rak J., Kerbel R.S.: "Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner". Oncogene, 2000, 19, 4611.

[75] Chen H.Y., Hsu C.T., Lin W.C., T sai H.D., Chang W.C.: "Prognostic value of nm23 expression in stage IBl cervical carcinoma". Jpn J. Clin. Oncol., 2001, 31, 327.

[76] Ravazoula P., Aletra C., Kourounis G., Ladopoulos I., Tzigounis V.: "Immunohistochemical analysis of nm23-Hl expression in human cervical lesions". Eur. J. Gynaecol. Oncol., 2000, 21, 510.

[77] al-Saleh W., Delvenne P., van den Brule F.A., Menard S., Boniver J., Castronovo V.: "Expression of the 67 KD laminin receptor in human cervical preneoplastic and neoplastic squamous epithelial lesions: an immunohistochemical study". J. Pathol., 1997, 181, 287.

[78] Demeter L.M., Stoler M.H., Sobel M.E., Broker T.R., Chow L.T.: "Expression of high-affinity laminin receptor mRNA correlates with cell proliferation rather than invasion in human papillomavirus-associated cervical neoplasms". Cancer Res., 1992, 52, 1561.

[79] Xue Y., Feng Y., Zhu G., Zhang X.: "Proliferative activity in cervical intraepithelial neoplasia and cervical carcinoma". Chin. Med. J., 1999, 112, 373.

[80] Tjalma W.A., Weyler J.J., Bogers J.J., Pollefliet C., Baay M., Goovaerts G.C et al.: "The importance of biological factors (bcl-2, bax, p53, PCNA, MI, HPV and angiogenesis) in invasive cervical cancer". Eur. J. Obstet. Gynecol. Reprod. [Jiol., 2001, 97, 223.

[81] Suk K., Kim Y.H., Chang I., Kim J.Y., Choi Y.H., Lee K.Y., Lee M.S.: "IFN-alpha sensitizes ME-180 human cervical cancer cells to TNFalpha-induced apoptosis by inhibiting cytoprotective NF-kappaB activation". FEBS Lett., 2001, 495, 66.

[82] Nees M., Geoghegan J.M., Hyman T., Frank S., Miller L., Woodworth C.D.: "Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes". J. Viral., 2001, 75, 4283.

[83] Davidson B., Goldberg I., Lerner-Geva L., Gotlieb W.H., Ben-Baruch G., Novikov I., Kopolovic J.: "Expression of topoisomerase II and Ki-67 in cervical carcinoma-clinicopathological study using immunohistochemistry". APMIS, 2000, 108, 209.

[84] Gibbons D., Fogt F., Kasznica J., Holden J., Nikulasson S.: "Comparison of topoisomerase II alpha and MIB-1 expression in uterine cervical squamous lesions". Mod. Pathol., 1997, 10, 409.

[85] Walker N.l., Harmon B.Y., Gobe G.C., Kerr J.F.R.: "Patterns of cell death". Meth. Achiev. Exp. Pathol., 1988, 13, 18

[86] Sagawa Y., Nishi H., Isaka K., Fujito A., Takayama M.: "The co订elation of TERT expression with c-myc expression in cervical cancer". Cancer Lett., 2001, 168, 45.

[87] Reddy V.G., Khanna N., Jain S.K., Das B.C., Singh N.: "Telomerase: A molecular marker for cervical cancer screening". Int. J Gynecol. Cancer, 2001, 11, 100.

[88] Saitoh Y., Yaginuma Y., Ishikawa M.: "Analysis of Bcl-2, Bax and Survivin genes in uterine cancer". Int. J. Oneal., 1999, 15, 137

[89] Wang M., Wang B., Wang X.: "A novel anti-apoptosis gene, survivin, bcl-2, p53 expression in cervical carcinomas". Zhonghua Fu Chan Ke Za Zhi., 2001, 36, 546.